Synthesis of a Novel Multifunctional Hybrid Drug as a Chemotherapeutic Treatment for Prostate Cancer

Loading...
Thumbnail Image
Authors
Sorensen, Kathleen M.
Issue Date
2016
Type
Thesis
Language
en_US
Keywords
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
An estimated 1 in 7 men will be diagnosed with prostate cancer, the second most common cancer among men within their lifetime. Currently, the chemotherapeutic treatments for prostate cancer have proven to be effective for a certain amount of time before the disease progresses to Castrate Resistant Prostate Cancer (CRPC) where the treatments are no longer as effective. In order to target prostate cancer before and after CRPC, a novel multifunctional hybrid drug is synthesized to test its abilities to block the androgen receptor (AR) to stop the proliferation of prostate cancer cells. Two cancer combating molecules were specifically chosen to be synthesized together due to their functionality and similar functional groups: enzalutamide and sulforaphane. Enzalutamide, a secondary antiandrogen, is a current chemotherapeutic drug administered to CRPC patients. Sulforaphane is a isothiocyanate found in cruciferous plants that demonstrates anticancer properties such as inhibiting cancer cell growth and induced cancer cell death. In this study, using thin layer chromatography and 1H NMR, a novel chemotherapeutic product, (s)-(1-(((6-(5-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)pyridine-2-yl)hexyl)carbamothioyl)thio)-3-oxobutan-2-yl)carbamic acid, was successfully synthesized as a potential anti-prostate cancer drug.
Description
vii, 32 p.
Citation
Publisher
Kalamazoo College
License
U.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder. All rights reserved.
Journal
Volume
Issue
PubMed ID
DOI
ISSN
EISSN